Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma

• Published in: Cancers Vol. 12; no. 2; p. 304
• Main Authors: Richter, Günther H S, Hensel, Tim, Schmidt, Oxana, Saratov, Vadim, von Heyking, Kristina, Becker-Dettling, Fiona, Prexler, Carolin, Yen, Hsi-Yu, Steiger, Katja, Fulda, Simone, Dirksen, Uta, Weichert, Wilko, Wang, Shudong, Burdach, Stefan, Schäfer, Beat W
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 28-01-2020
• Subjects: CDK9; combination therapy; tumor growth; Ewing sarcoma; BRD4
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12020304

Previously, we used inhibitors blocking BET bromodomain binding proteins (BRDs) in Ewing sarcoma (EwS) and observed that long term treatment resulted in the development of resistance. Here, we analyze the possible interaction of BRD4 with cyclin-dependent kinase (CDK) 9.
Co-immunoprecipitation experiments (CoIP) to characterize BRD4 interaction and functional consequences of inhibiting transcriptional elongation were assessed using drugs targeting of BRD4 or CDK9, either alone or in combination.
CoIP revealed an interaction of BRD4 with EWS-FLI1 and CDK9 in EwS. Treatment of EwS cells with CDKI-73, a specific CDK9 inhibitor (CDK9i), induced a rapid downregulation of EWS-FLI1 expression and block of contact-dependent growth. CDKI-73 induced apoptosis in EwS, as depicted by cleavage of Caspase 7 (CASP7), PARP and increased CASP3 activity, similar to JQ1. Microarray analysis following CDKI-73 treatment uncovered a transcriptional program that was only partially comparable to BRD inhibition. Strikingly, combined treatment of EwS with BRD- and CDK9-inhibitors re-sensitized cells, and was overall more effective than individual drugs not only in vitro but also in a preclinical mouse model in vivo.
Treatment with BRD inhibitors in combination with CDK9i offers a new treatment option that significantly blocks the pathognomonic EWS-ETS transcriptional program and malignant phenotype of EwS.